Article

A transcriptional signature of LKB1 functional loss defines a large, therapeutically addressable patient population across human cancers

2026-07-24

Abstract excerpt

Loss of the tumor suppressor LKB1 (STK11) drives metabolic reprogramming and immune evasion, but its clinical footprint is defined almost entirely by somatic mutation and deletion. Because emerging therapies aim to reactivate this pathway in structurally wild-type tumors, defining the full LKB1-deficient population (including tumors silenced by non-genomic mechanisms) is a prerequisite for patient selection. We de...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9a020316-67c6-5434-a8e1-dcf54c04dab7
DOI: 10.64898/2026.07.23.740219

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A transcriptional signature of LKB1 functional loss defines a large, therapeutically addressable patient population across human cancersDOI 10.64898/2026.07.23.740219Read

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact.Semantic proximity Read

Multiomic profiling of LKB1 loss of expression in breast cancerSemantic proximity Read

LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.Semantic proximity Read

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Semantic proximity Read

High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma.Semantic proximity Read

Tumor loss-of-function mutations in STK11/LKB1 induce cachexia.Semantic proximity Read

LKB1 inactivation modulates chromatin accessibility to drive metastatic progression.Semantic proximity Read

Distinct molecular subtypes of KRASG12C-mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies.Semantic proximity Read

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.Semantic proximity Read

STK11/LKB1 Loss of Function Is Associated with Global DNA Hypomethylation and S-Adenosyl-Methionine Depletion in Human Lung Adenocarcinoma.Semantic proximity Read

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC.Semantic proximity Read